Pimavanserin: novel pharmacotherapy for Parkinson’s disease psychosis

References

• Tolosa E, Wenning G, Poewe W. The diagnosis of Parkinson’s disease. Lancet Neurol. 2006;5(1):75–86.
   PubMed Web of Science ®Google Scholar
• Jankovic J. Parkinson’s disease: clinical features and diagnosis. J Neurol Neurosurg Psychiatry. 2008;79(4):368–376.
   PubMed Web of Science ®Google Scholar
• Pahwa R, Lyons KE. Early diagnosis of Parkinson’s disease: recommendations from diagnostic clinical guidelines. Am J Manag Care. 2010;16 Suppl Implications: S94-S99. Available from: https://www.ncbi.nlm.nih.gov/pubmed/20297872
   PubMed Web of Science ®Google Scholar
• Hermanowicz N. Management of Parkinson’s disease. Strategies, pitfalls, and future directions. Postgrad Med. 2001;110(6):15-8,21-3,28.
   PubMed Web of Science ®Google Scholar
• Piccini P, Whone A. Functional brain imaging in the differential diagnosis of Parkinson’s disease. Lancet Neurol. 2004;3(5):284–290.
   PubMed Web of Science ®Google Scholar
• Piccini P, Brooks DJ. New developments of brain imaging for Parkinson’s disease and related disorders. Mov Disord. 2006;21(12):2035–2041.
   PubMed Web of Science ®Google Scholar
• Forsaa EB, Larsen JP, Wentzel-Larsen T, et al. A 12-year population-based study of psychosis in Parkinson disease. Arch Neurol. 2010;67(8):996–1001.
   PubMedGoogle Scholar
• Ravina B, Marder K, Fernandez HH, et al. Diagnostic criteria for psychosis in Parkinson’s disease: report of an NINDS, NIMH work group. Mov Disord. 2007;22(8):1061–1068.
   PubMed Web of Science ®Google Scholar
• Kempster PA, O’Sullivan SS, Holton JL, et al. Relationships between age and late progression of Parkinson’s disease: a clinico-pathological study. Brain. 2010 Apr 5;133(6):1755–1762.
   PubMed Web of Science ®Google Scholar
• Chou KL, Messing S, Oakes D, et al. Drug-induced psychosis in Parkinson disease: phenomenology and correlations among psychosis rating instruments. Clin Neuropharmacol. 2005;28(5):215–219.
   PubMed Web of Science ®Google Scholar
• Friedman JH. Parkinson disease psychosis: update. Behav Neurol. 2013;27(4):469–477.
   PubMed Web of Science ®Google Scholar
• Fénelon G, Alves G. Epidemiology of psychosis in Parkinson’s disease. J Neurol Sci. 2010;289(1):12–17.
   PubMed Web of Science ®Google Scholar
• Holroyd S, Currie L, Wooten G. Prospective study of hallucinations and delusions in Parkinson’s disease. J Neurol Neurosurg Psychiatry. 2001;70(6):734–738.
   PubMed Web of Science ®Google Scholar
• Postuma RB, Bertrand JA, Montplaisir J, et al. Rapid eye movement sleep behavior disorder and risk of dementia in Parkinson’s disease: a prospective study. Mov Disord. 2012;27(6):720–726.
   PubMed Web of Science ®Google Scholar
• Biglan KM, Holloway RG, McDermott MP, et al. Risk factors for somnolence, edema, and hallucinations in early Parkinson disease. Neurology. 2007;69(2):187–195.
   PubMed Web of Science ®Google Scholar
• Kiziltan G, Özekmekçi S, Ertan S, et al. Relationship between age and subtypes of psychotic symptoms in Parkinson’s disease. J Neurol. 2007;254(4):448–452.
   PubMed Web of Science ®Google Scholar
• Ecker D, Unrath A, Kassubek J, et al. Dopamine Agonists and their risk to induce psychotic episodes in Parkinson’s disease: a case-control study. BMC Neurol. 2009;9:23.
   PubMed Web of Science ®Google Scholar
• Aarsland D, Larsen JP, Tandberg E, et al. Predictors of nursing home placement in Parkinson’s disease: a population-based, prospective study. J Am Geriatr Soc. 2000;48:938–942.
   PubMed Web of Science ®Google Scholar
• Klein C, Prokhorov T, Miniovitz A, et al. Admission of Parkinsonian patients to a neurological ward in a community hospital. J Neural Transm. 2009;116(11):1509–1512.
   PubMed Web of Science ®Google Scholar
• Forsaa E, Larsen J, Wentzel-Larsen T, et al. What predicts mortality in Parkinson disease? A prospective population-based long-term study. Neurology. 2010;75(14):1270–1276.
   PubMed Web of Science ®Google Scholar
• Kalaitzakis M, Christian L, Moran L, et al. Dementia and visual hallucinations associated with limbic pathology in Parkinson’s disease. Parkinsonism Relat Disord. 2009;15(3):196–204.
   PubMed Web of Science ®Google Scholar
• Gallagher DA, Parkkinen L, O’Sullivan SS, et al. Testing an aetiological model of visual hallucinations in Parkinson’s disease. Brain. 2011;134(11):3299–3309.
   PubMed Web of Science ®Google Scholar
• Goetz C, Pappert E, Blasucci L, et al. Intravenous levodopa in hallucinating Parkinson’s disease patients: high‐dose challenge does not precipitate hallucinations. Neurology. 1998;50(2):515–517.
   PubMed Web of Science ®Google Scholar
• Papapetropoulos S, McCorquodale DS, Gonzalez J. Cortical and amygdalar Lewy body burden in Parkinson’s disease patients with visual hallucinations. Parkinsonism Relat Disord. 2006;12(4):253–256.
   PubMed Web of Science ®Google Scholar
• Huot P, Fox SH. The serotonergic system in motor and non-motor manifestations of Parkinson’s disease. Exp Brain Res. 2013;230(4):463–476.
   PubMed Web of Science ®Google Scholar
• Joutsa J, Johansson J, Seppänen M, et al. Dorsal-to-ventral shift in midbrain dopaminergic projections and increased thalamic/raphe serotonergic function in early Parkinson disease. J Nucl Med. 2015;56(7):1036–1041.
   PubMed Web of Science ®Google Scholar
• Ballanger B, Strafella AP, van Eimeren T, et al. Serotonin 2A receptors and visual hallucinations in Parkinson disease. Arch Neurol. 2010;67:416–421.
   PubMed Web of Science ®Google Scholar
• Huot P, Johnston TH, Darr T, et al. Increased 5‐HT2A receptors in the temporal cortex of parkinsonian patients with visual hallucinations. Mov Disord. 2010;25(10):1399–1408.
   PubMed Web of Science ®Google Scholar
• Hacksell U, Burstein ES, McFarland K, et al. On the discovery and development of pimavanserin: a novel drug candidate for Parkinson’s psychosis. Neurochem Res. 2014;39(10):2008–2017.
   PubMed Web of Science ®Google Scholar
• Thomsen TR, Panisset M, Suchowersky O, et al. Impact of standard of care for psychosis in Parkinson disease. J Neurolo Neurosurg Psychiatry. 2008 Dec 1;79(12):1413–1415.
   PubMed Web of Science ®Google Scholar
• Targum SD. Treating psychotic symptoms in elderly patients. Prim Care Companion J Clin Psychiatry. 2001;3(4):156–163.
   PubMedGoogle Scholar
• Minett TS, Thomas A, Wilkinson LM, et al. What happens when donepezil is suddenly withdrawn? An open label trial in dementia with Lewy bodies and Parkinson’s disease with dementia. Int J Geriatr Psychiatry. 2003;18:988–993.
   PubMed Web of Science ®Google Scholar
• Perry EK, Marshall E, Kerwin J, et al. Evidence of a monoaminergic-cholinergic imbalance related to visual hallucinations in Lewy body dementia. J Neurochem. 1990;55:1454–1456.
   PubMed Web of Science ®Google Scholar
• Fabbrini G, Barbanti P, Aurilia C, et al. Donepezil in the treatment of hallucinations and delusions in Parkinson’s disease. Neurological Sci. 2002 Apr 19;23(1):41–43.
   PubMed Web of Science ®Google Scholar
• van Laar T, De Deyn PP, Aarsland D, et al. Effects of cholinesterase inhibitors in Parkinson’s disease dementia: a review of clinical data. CNS Neurosci Ther. 2011 Oct 1;17(5):428–441.
   PubMed Web of Science ®Google Scholar
• Ondo WG, Levy JK, Vuong KD, et al. Olanzapine treatment for dopaminergic‐induced hallucinations. Mov Disord. 2002;17(5):1031–1035.
   PubMed Web of Science ®Google Scholar
• Mohr E, Mendis T, Hildebrand K, et al. Risperidone in the treatment of dopamine‐induced psychosis in Parkinson’s disease: an open pilot trial. Mov Disord. 2000;15(6):1230–1237.
   PubMed Web of Science ®Google Scholar
• Berkowitz AL. Ziprasidone therapy in elderly patients with psychotic mood disorders and Parkinson’s disease. Psychiatry (Edgmont). 2006;3(11):59–63.
   PubMedGoogle Scholar
• Wickremaratchi M, Morris HR, Ali IM. Aripiprazole associated with severe exacerbation of Parkinson’s disease. Mov Disord. 2006;21(9):1538–1539.
   PubMed Web of Science ®Google Scholar
• Weintraub D, Chen P, Ignacio RV, et al. Patterns and trends in antipsychotic prescribing for Parkinson disease psychosis. Arch Neurol. 2011;68(7):899–904.
   PubMedGoogle Scholar
• Brunello N, Masotto C, Steardo L, et al. New insights into the biology of schizophrenia through the mechanism of action of clozapine. Neuropsychopharmacol. 1995;13(3):177–213.
   PubMed Web of Science ®Google Scholar
• Wolters EC, Berendse HW. Management of psychosis in Parkinson’s disease. Curr Opin Neurol. 2001;14(4):499–504.
   PubMed Web of Science ®Google Scholar
• Baldessarini RJ, Frankenburg FR. Clozapine – a novel antipsychotic agent. N Engl J Med. 1991;324:746–754.
   PubMed Web of Science ®Google Scholar
• Nord M, Nyberg S, Brogren J, et al. Comparison of D2 dopamine receptor occupancy after oral administration of quetiapine fumarate immediate-release and extended-release formulations in healthy subjects. Int J Neuropsychopharmacol. 2011;14(10):1357–1366.
   PubMed Web of Science ®Google Scholar
• Shotbolt P, Samuel M, David A. Quetiapine in the treatment of psychosis in Parkinson’s disease. Ther Adv Neurol Disord. 2010;3(6):339–350.
   PubMedGoogle Scholar
• Schneider LS, Dagerman KS, Insel P. Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. JAMA. 2005;294(15):1934–1943.
   PubMed Web of Science ®Google Scholar
• Ballard C, Isaacson S, Mills R, et al. Impact of current antipsychotic medications on comparative mortality and adverse events in people with Parkinson disease psychosis. J Am Med Dir Assoc. 2015;16(10):898.e1-7.
   Web of Science ®Google Scholar
• Meco G, Bernardi S. Antidepressant use in treatment of psychosis with comorbid depression in Parkinson’s disease. Prog Neuropsychopharmacol Biol Psychiatry. 2007;31:311–313.
   PubMed Web of Science ®Google Scholar
• Voon V, Fox S, Butler TR, et al. Antidepressants and psychosis in Parkinson disease: a case series. Int J Geriatr Psychiatry. 2007;22:601–604.
   PubMed Web of Science ®Google Scholar
• Tagai K, Nagata T, Shinagawa S, et al. Mirtazapine improves visual hallucinations in Parkinson’s disease: a case report. Psychogeriatrics. 2013;13:103–107.
   PubMed Web of Science ®Google Scholar
• Lauterbach EC. Dopaminergic hallucinosis with fluoxetine in Parkinson’s disease. Am J Psychiatry. 1993;150:1750.
   PubMed Web of Science ®Google Scholar
• Normann C, Hesslinger B, Frauenknecht S, et al. Psychosis during chronic levodopa therapy triggered by the new antidepressive drug mirtazapine. Pharmacopsychiatry. 1997;30:263–265.
   PubMed Web of Science ®Google Scholar
• Weiner DM, Burstein ES, Nash N, et al. 5-Hydroxytriptamine2A receptor inverse agonists as antipsychotics. J Pharmacol Exp Ther. 2001;299:268–276.
   PubMed Web of Science ®Google Scholar
• Nordstrom AL, Mansson M, Jovanovic H, et al. PET analysis of the 5-HT2A receptor inverse agonist ACP-103 in human brain. Int J Neuropsychopharmacol. 2008;11(2):163–171.
   PubMed Web of Science ®Google Scholar
• Meltzer HY, Mills R, Revell S, et al. Pimavanserin, a serotonin2A receptor inverse agonist, for the treatment of Parkinson’s disease psychosis. Neuropsychopharmacology. 2010;35(4):881–892.
   PubMed Web of Science ®Google Scholar
• McFarland K, Price DL, Bonhaus DW. Pimavanserin, a 5-HT2A inverse agonist, reverses psychosis-like behaviors in a rodent model of Parkinson’s disease. Behav Pharmacol. 2011;22(7):681–692.
   PubMed Web of Science ®Google Scholar
• Vanover KE, Weiner DM, Makhay M, et al. Pharmacological and behavioral profile of N-(4-fluorophenylmethyl)-N-(1-methylpiperidin-4-yl)-N’-(4-(2-methylpropyloxy)-phenylmethyl) carbamide (2R,3R)-dihydroxybutanedioate (2:1) (ACP-103), a novel 5-hydroxytryptamine(2A) receptor inverse agonist. J Pharmacol Exp Ther. 2006;317(2):910–918.
   PubMed Web of Science ®Google Scholar
• Vanover KE, Robbins‐Weilert D, Wilbraham DG, et al. The effects of food on the pharmacokinetics of a formulated ACP‐103 tablet in healthy volunteers. J Clin Pharmacol. 2007;47(7):915–919.
   PubMed Web of Science ®Google Scholar
• Vanover KE, Robbins‐Weilert D, Wilbraham DG, et al. Pharmacokinetics, tolerability, and safety of ACP‐103 following single or multiple oral dose administration in healthy volunteers. J Clin Pharmacol. 2007;47(6):704–714.
   PubMed Web of Science ®Google Scholar
• Nuplazid (pimavanserin) prescribing information-2016.
   Google Scholar
• Bozymski KM, Lowe DK, Pasternak KM, et al. Pimavanserin: a novel antipsychotic for Parkinson’s disease psychosis. Ann Pharmacother. 2017;51:479–487.
   PubMed Web of Science ®Google Scholar
• Cummings J, Isaacson S, Mills R, et al. Pimavanserin for patients with Parkinson’s disease psychosis: a randomised, placebo-controlled phase 3 trial. Lancet. 2014;383(9916):533–540.
   PubMed Web of Science ®Google Scholar
• Voss T, Bahr D, Cummings J, et al. Performance of a shortened scale for assessment of positive symptoms for Parkinson’s disease psychosis. Parkinsonism Relat Disord. 2013;19(3):295–299.
   PubMed Web of Science ®Google Scholar
• Mills R, Johnson AD, Williams H, et al. An open-label extension study to determine the safety of pimavanserin in patients with Parkinson’s disease and psychosis. Mov Disord. 2009;24:S269.
   Web of Science ®Google Scholar
• Ballard C, Mills R, Williams H, et al. Antipsychotic efficacy and good tolerability in a phase III placebo-controlled study of pimavanserin in patients with Parkinson’s disease psychosis (ACP-103-020). Alzheimers Dement. 2013;9(4):P690.
   Google Scholar
• Parkinson Study Group. Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson’s disease. N Engl J Med. 1999 Mar 11;1999(340):757–763.
   Google Scholar
• Gardell LR, Vanover KE, Pounds L, et al. ACP-103, a 5-hydroxytryptamine 2A receptor inverse agonist, improves the antipsychotic efficacy and side-effect profile of haloperidol and risperidone in experimental models. J Pharmacol Exp Ther. 2007;322(2):862–870.
   PubMed Web of Science ®Google Scholar
• Meltzer HY, Elkis H, Vanover K, et al. Pimavanserin, a selective serotonin (5-HT)2A-inverse agonist, enhances the efficacy and safety of risperidone, 2mg/day, but does not enhance efficacy of haloperidol, 2mg/day: comparison with reference dose risperidone, 6mg/day. Schizophr Res. 2012;141(2–3):144–152.
   PubMed Web of Science ®Google Scholar
• Price DL, Bonhaus DW, McFarland K. Pimavanserin, a 5-HT2A receptor inverse agonist, reverses psychosis-like behaviors in a rodent model of Alzheimer’s disease. Behav Pharmacol. 2012;23(4):426–433.
   PubMed Web of Science ®Google Scholar
• Acadia Pharmaceuticals Press Release. Acadia Pharmaceuticals announces positive top-line results from phase II study of pimavanserin for Alzheimer’s disease psychosis. Dec 20 2016.
   Google Scholar
• Acadia Pharmaceuticals Press Release. Acadia Pharmaceuticals initiates phase III study of pimavanserin in dementia-related psychosis. Oct 4 2017.
   Google Scholar
• Acadia Pharmaceticals Inc. A study of pimavanserin for the treatment of agitation and aggression in subjects with Alzheimer’s disease. ClinicalTrials.gov Identifier: NCT03118947
   Google Scholar
• Acadia Pharmaceuticals Inc. Efficacy and safety of pimavanserin as adjunctive treatment for negative symptoms of schizophrenia (ADVANCE). ClinicalTrials.gov Identifier: NCT02970305
   Google Scholar
• Acadia Pharmaceuticals Inc. Study to evaluate the efficacy and safety of adjunctive pimavanserin in major depressive disorder (CLARITY). ClinicalTrials.gov Identifier: NCT03018340
   Google Scholar